Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab in early Alzheimer's disease
NCT04381468Phase 2Completed
- Sponsor
- Vaccinex, Inc.
- Start
- Jul 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Pepinemab 40 mg/kg with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 40 weeks. Started Jul 2021; status: completed.
02
Drugs
pepinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04381468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381468.